Literature DB >> 9517397

Comparison of relaxin receptors in rat isolated atria and uterus by use of synthetic and native relaxin analogues.

Y Y Tan1, J D Wade, G W Tregear, R J Summers.   

Abstract

1. The receptors for relaxin in the rat atria and uterus were investigated and compared by use of a series of synthetic and native relaxin analogues. The assays used were the positive chronotropic and inotropic effects in rat spontaneously beating, isolated right atrium and electrically driven left atrium and the relaxation of K+ precontracted uterine smooth muscle. 2. Relaxin analogues with an intact A- and B-chain were active in producing powerful chronotropic and inotropic effects in the rat isolated atria at nanomolar concentrations. Single-chain analogues and structural homologues of relaxin such as human insulin and sheep insulin-like growth factor I had no agonist action and did not antagonize the effect of the B29 form of human gene 2 relaxin. 3. Shortening the B-chain carboxyl terminal of human gene 1 (B2-29) relaxin to B2-26 reduced the activity of the peptide and removal of another 2 amino acid residues (B2-24) abolished the activity. This suggests that the B-chain length may be important for determination of the activity of relaxin. More detailed studies are needed to determine the effect of progressive amino acid removal on the structure and the bioactivity of relaxin. 4. Porcine prorelaxin was as active as porcine relaxin on a molar basis, suggesting that the presence of the intact C-peptide did not affect the binding of the prorelaxin to the receptor to produce functional responses. 5. Relaxin caused relaxation of uterine longitudinal and circular smooth muscle precontracted with 40 mM K+. The pEC50 values for human gene 2 and porcine relaxins were lower than those in the atrial assay, but rat relaxin had similar pEC50 values in both atrial and uterine assays. Rat relaxin was significantly less potent than either human gene 2 or porcine relaxin in the atrial assay, but in the uterine assay they were equipotent. The results suggest that the relaxin receptor or the signalling pathway in rat atria may differ from that in the uterus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517397      PMCID: PMC1565217          DOI: 10.1038/sj.bjp.0701659

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Relaxin increases sympathetic nerve activity and activates spinally projecting neurons in the paraventricular nucleus of nonpregnant, but not pregnant, rats.

Authors:  K Max Coldren; Randall Brown; Eileen M Hasser; Cheryl M Heesch
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-09-23       Impact factor: 3.619

Review 2.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 3.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 4.  Relaxin family peptides: structure-activity relationship studies.

Authors:  Nitin A Patil; K Johan Rosengren; Frances Separovic; John D Wade; Ross A D Bathgate; Mohammed Akhter Hossain
Journal:  Br J Pharmacol       Date:  2017-01-19       Impact factor: 8.739

5.  Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: characterization and effects of oestrogen treatment.

Authors:  Y Y Tan; J D Wade; G W Tregear; R J Summers
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

6.  Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin.

Authors:  Andrew R Kompa; Chrishan S Samuel; Roger J Summers
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 7.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

8.  Ligand-activated RXFP1 gene therapy ameliorates pressure overload-induced cardiac dysfunction.

Authors:  Nuttarak Sasipong; Philipp Schlegel; Julia Wingert; Christoph Lederer; Eric Meinhardt; Amelie Ziefer; Constanze Schmidt; Kleopatra Rapti; Cornelia Thöni; Norbert Frey; Patrick Most; Hugo A Katus; Philip W J Raake
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 12.910

9.  Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-Mediated Airway Relaxation.

Authors:  Maggie Lam; Simon G Royce; Chantal Donovan; Maria Jelinic; Laura J Parry; Chrishan S Samuel; Jane E Bourke
Journal:  Front Pharmacol       Date:  2016-10-27       Impact factor: 5.810

10.  Evolution of the relaxin/insulin-like gene family in anthropoid primates.

Authors:  José Ignacio Arroyo; Federico G Hoffmann; Juan C Opazo
Journal:  Genome Biol Evol       Date:  2014-03       Impact factor: 3.416

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.